| Year |
Citation |
Score |
| 2021 |
Amaya M, Inguva A, Pei S, Jones CL, Krug A, Ye H, Minhajuddin M, Winters AC, Furtek SL, Gamboni F, Stevens BM, D'Alessandro A, Pollyea DA, Reigan P, Jordan CT. The STAT3-MYC Axis Promotes Survival of Leukemia Stem Cells by Regulating SLC1A5 and Oxidative Phosphorylation. Blood. PMID 34525179 DOI: 10.1182/blood.2021013201 |
0.339 |
|
| 2021 |
Chavez JS, Rabe JL, Loeffler D, Higa KC, Hernandez G, Mills TS, Ahmed N, Gessner RL, Ke Z, Idler BM, Niño KE, Kim H, Myers JR, Stevens BM, Davizon-Castillo P, ... Jordan CT, et al. PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress. The Journal of Experimental Medicine. 218. PMID 33857288 DOI: 10.1084/jem.20201169 |
0.305 |
|
| 2021 |
Jones CL, Inguva A, Jordan CT. Targeting Energy Metabolism in Cancer Stem Cells: Progress and Challenges in Leukemia and Solid Tumors. Cell Stem Cell. 28: 378-393. PMID 33667359 DOI: 10.1016/j.stem.2021.02.013 |
0.332 |
|
| 2021 |
Stevens BM, O'Brien C, Jordan CT, Jones CL. Enriching for human acute myeloid leukemia stem cells using reactive oxygen species-based cell sorting. Star Protocols. 2: 100248. PMID 33437968 DOI: 10.1016/j.xpro.2020.100248 |
0.312 |
|
| 2020 |
Fisher MH, Kirkpatrick GD, Stevens BM, Jones CL, Callaghan MU, Rajpurkar M, Fulbright J, Cooper MA, Rowley J, Porter CC, Gutierrez-Hartmann A, Jones K, Jordan CT, Pietras EM, Di Paola J. ETV6 germline mutations cause HDAC3/NCOR2 mislocalization and upregulation of interferon response genes. Jci Insight. PMID 32841218 DOI: 10.1172/Jci.Insight.140332 |
0.332 |
|
| 2020 |
Jones CL, Stevens BM, Pollyea DA, Culp-Hill R, Reisz JA, Nemkov T, Gehrke S, Gamboni F, Krug A, Winters A, Pei S, Gustafson A, Ye H, Inguva A, Amaya M, ... ... Jordan CT, et al. Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells. Cell Stem Cell. PMID 32822582 DOI: 10.1016/J.Stem.2020.07.021 |
0.349 |
|
| 2020 |
Yang C, Chen F, Ren P, Lofchy L, Wan C, Shen J, Wang G, Gaikwad H, Ponder J, Jordan CT, Scheinman R, Simberg D. Delivery of a model lipophilic membrane cargo to bone marrow via cell-derived microparticles. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 32682903 DOI: 10.1016/J.Jconrel.2020.07.019 |
0.395 |
|
| 2020 |
Matheson CJ, Casalvieri KA, Backos DS, Minhajuddin M, Jordan CT, Reigan P. Substituted oxindol-3-ylidenes as AMP-activated protein kinase (AMPK) inhibitors. European Journal of Medicinal Chemistry. 197: 112316. PMID 32334266 DOI: 10.1016/J.Ejmech.2020.112316 |
0.366 |
|
| 2020 |
Walker ZJ, VanWyngarden MJ, Stevens BM, Abbott D, Hammes A, Langouët-Astrie C, Smith CA, Palmer BE, Forsberg PA, Mark TM, Jordan CT, Sherbenou DW. Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression. Blood Advances. 4: 1628-1639. PMID 32311014 DOI: 10.1182/Bloodadvances.2019000122 |
0.332 |
|
| 2020 |
Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, Riemondy KA, Gillen AE, Sheridan RM, Kim J, Costello JC, Amaya ML, Inguva A, Winters A, Ye H, ... ... Jordan CT, et al. Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Acute Myeloid Leukemia Patients. Cancer Discovery. PMID 31974170 DOI: 10.1158/2159-8290.Cd-19-0710 |
0.347 |
|
| 2019 |
Jordan CT. Can we selectively target AML stem cells? Best Practice & Research. Clinical Haematology. 32: 101100. PMID 31779978 DOI: 10.1016/J.Beha.2019.101100 |
0.387 |
|
| 2019 |
Stevens BM, Zhang W, Pollyea DA, Winters A, Gutman J, Smith C, Budde E, Forman SJ, Jordan CT, Purev E. CD123 CAR T Cells for the Treatment of Myelodysplastic Syndrome. Experimental Hematology. PMID 31136781 DOI: 10.1016/J.Exphem.2019.05.002 |
0.424 |
|
| 2019 |
Hernandez G, Mills TS, Rabe JL, Chavez JS, Kuldanek S, Kirkpatrick G, Noetzli L, Jubair WK, Zanche M, Meyers JR, Stevens BM, Fleenor CJ, Adane B, Dinarello CA, Ashton J, ... Jordan CT, et al. Pro-inflammatory cytokine blockade attenuates myeloid expansion in a murine model of rheumatoid arthritis. Haematologica. PMID 31101752 DOI: 10.3324/Haematol.2018.197210 |
0.392 |
|
| 2019 |
Jones CL, Stevens BM, D'Alessandro A, Culp-Hill R, Reisz JA, Pei S, Gustafson A, Khan N, DeGregori J, Pollyea DA, Jordan CT. Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II. Blood. PMID 31101624 DOI: 10.1182/Blood.2019898114 |
0.393 |
|
| 2019 |
Stevens B, Winters A, Gutman JA, Fullerton A, Hemenway G, Schatz D, Miltgen N, Wei Q, Abbasi T, Vali S, Singh NK, Drusbosky L, Cogle CR, Hammes A, Abbott D, ... Jordan CT, et al. Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis. Leukemia Research. 81: 43-49. PMID 31009835 DOI: 10.1016/J.Leukres.2019.04.005 |
0.308 |
|
| 2019 |
Adane B, Ye H, Khan N, Pei S, Minhajuddin M, Stevens BM, Jones CL, D'Alessandro A, Reisz JA, Zaberezhnyy V, Gasparetto M, Ho TC, Kelly KK, Myers JR, Ashton JM, ... ... Jordan CT, et al. The Hematopoietic Oxidase NOX2 Regulates Self-Renewal of Leukemic Stem Cells. Cell Reports. 27: 238-254.e6. PMID 30943405 DOI: 10.1016/J.Celrep.2019.03.009 |
0.435 |
|
| 2019 |
Gregory MA, Nemkov T, Park HJ, Zaberezhnvv V, Gehrke S, Adane B, Jordan CT, Hansen KC, D'Alessandro A, DeGregori J. Targeting glutamine metabolism and redox state for leukemia therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30940653 DOI: 10.1158/1078-0432.Ccr-18-3223 |
0.408 |
|
| 2019 |
Pollyea DA, Jordan CT. Why are hypomethylating agents or low-dose cytarabine and venetoclax so effective? Current Opinion in Hematology. 26: 71-76. PMID 30652974 DOI: 10.1097/Moh.0000000000000485 |
0.308 |
|
| 2019 |
Pei S, Pollyea DA, Gustafson A, Minhajuddin M, Stevens BM, Ye H, Inguva A, Amaya ML, Krug A, Jones CL, Adane B, Winters A, Khan N, Ponder J, Schowinsky J, ... ... Jordan CT, et al. Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy Blood. 134: 185-185. DOI: 10.1182/Blood-2019-131390 |
0.399 |
|
| 2019 |
Chavez J, Rabe JL, Higa K, Loeffler D, Nouraiz A, Mills T, Idler BM, Stevens BM, Fleenor C, Nerlov C, Nakajima H, Hagman J, Schroeder T, Kim HM, Jordan CT, et al. PU.1 Enforces Hematopoietic Stem Cell Quiescence during Chronic Inflammation Blood. 134: 822-822. DOI: 10.1182/Blood-2019-129300 |
0.412 |
|
| 2019 |
Kaner JD, Tavakkoli M, Toudic L, Stevens BM, Jordan CT, Taldone T, Chiosis G, Ritchie EK, Desai P, Samuel MB, Lee S, Roboz GJ, Guzman ML. PTPN11 Mutated Acute Myeloid Leukemia (AML) Features an Abundant Epichaperome Network and Is Sensitive to the Epichaperome Inhibitor PU-H71 Blood. 134: 3935-3935. DOI: 10.1182/Blood-2019-128276 |
0.34 |
|
| 2019 |
Amaya ML, Inguva A, Jones CL, Krug A, Pei S, Reigan P, Jordan CT. STAT3 Plays a Critical Role in Mitochondrial Function and Survival of Primary AML Cells Blood. 134: 1275-1275. DOI: 10.1182/Blood-2019-127669 |
0.31 |
|
| 2019 |
Jones CL, Stevens BM, Culp-Hill R, Dalessandro A, Krug A, Goosman M, Pei S, Pollyea DA, Jordan CT. Inhibition of Fatty Acid Metabolism Re-Sensitizes Resistant Leukemia Stem Cells to Venetoclax with Azacitidine Blood. 134: 1272-1272. DOI: 10.1182/Blood-2019-125773 |
0.409 |
|
| 2019 |
Winters A, Gutman JA, Purev E, Stevens BM, Pei S, Schowinsky J, Abbott D, Hammes A, Nakic M, Lyle L, Halsema K, Macero D, Hirose A, Boggs C, Falco A, ... ... Jordan CT, et al. Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy Blood. 134: 2638-2638. DOI: 10.1182/Blood-2019-122120 |
0.312 |
|
| 2019 |
Walker ZJ, Idler BM, VanWyngarden MJ, Stevens BM, Bearrows SC, Davis LN, Hammes A, Smith C, Jordan CT, Mark TM, Forsberg PA, Sherbenou DW. Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples Blood. 134: 4404-4404. DOI: 10.1182/Blood-2019-121937 |
0.427 |
|
| 2019 |
Matheson CJ, Casalvieri KA, Backos DS, Jordan CT, Reigan P. Abstract C078: Substituted oxindoles as AMP-activated protein kinase (AMPK) inhibitors and their evaluation in models of leukemia Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-C078 |
0.403 |
|
| 2018 |
Jones CL, Stevens BM, D'Alessandro A, Reisz JA, Culp-Hill R, Nemkov T, Pei S, Khan N, Adane B, Ye H, Krug A, Reinhold D, Smith C, DeGregori J, Pollyea DA, ... Jordan CT, et al. Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. Cancer Cell. 34: 724-740.e4. PMID 30423294 DOI: 10.1182/Blood-2018-99-111965 |
0.37 |
|
| 2018 |
Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, D'Alessandro A, Culp-Hill R, Riemondy KA, Gillen AE, Hesselberth JR, Abbott D, Schatz D, Gutman JA, Purev E, ... ... Jordan CT, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nature Medicine. PMID 30420752 DOI: 10.1038/S41591-018-0233-1 |
0.423 |
|
| 2018 |
Lee-Sherick AB, Jacobsen KM, Henry CJ, Huey MG, Parker RE, Page LS, Hill AA, Wang X, Frye SV, Earp HS, Jordan CT, DeRyckere D, Graham DK. MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. Jci Insight. 3. PMID 30385715 DOI: 10.1172/Jci.Insight.97941 |
0.365 |
|
| 2018 |
Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, ... ... Jordan CT, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. PMID 30333627 DOI: 10.1038/S41586-018-0623-Z |
0.324 |
|
| 2018 |
Ye H, Adane B, Khan N, Alexeev E, Nusbacher N, Minhajuddin M, Stevens BM, Winters AC, Lin X, Ashton JM, Purev E, Xing L, Pollyea DA, Lozupone CA, Serkova NJ, ... ... Jordan CT, et al. Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells. Cancer Cell. PMID 30270124 DOI: 10.1016/J.Ccell.2018.08.016 |
0.309 |
|
| 2018 |
Stevens BM, Khan N, D'Alessandro A, Nemkov T, Winters A, Jones CL, Zhang W, Pollyea DA, Jordan CT. Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes. Nature Communications. 9: 3694. PMID 30209285 DOI: 10.1038/S41467-018-05984-X |
0.468 |
|
| 2018 |
Janganati V, Ponder J, Balasubramaniam M, Bhat-Nakshatri P, Bar EE, Nakshatri H, Jordan CT, Crooks PA. MMB triazole analogs are potent NF-κB inhibitors and anti-cancer agents against both hematological and solid tumor cells. European Journal of Medicinal Chemistry. 157: 562-581. PMID 30121494 DOI: 10.1016/J.Ejmech.2018.08.010 |
0.345 |
|
| 2018 |
Pei S, Minhajuddin M, Adane B, Khan N, Stevens BM, Mack SC, Lai S, Rich JN, Inguva A, Shannon KM, Kim H, Tan AC, Myers JR, Ashton JM, Neff T, ... ... Jordan CT, et al. AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell. PMID 29910151 DOI: 10.1016/J.Stem.2018.05.021 |
0.46 |
|
| 2018 |
Mills T, Hernandez G, Rabe JL, Kuldanek S, Chavez J, Kirkpatrick G, Noetzli L, Jubair W, Zanche M, Myers JR, Stevens BM, Fleenor C, Adane B, Ashton JM, Jordan CT, et al. Rheumatoid Arthritis Causes Hematopoietic Stem Cell Reprogramming to Maintain Functionality Blood. 132: 2573-2573. DOI: 10.1182/Blood-2018-99-120272 |
0.424 |
|
| 2018 |
Stevens BM, Jones CL, Winters A, Dugan J, Abbott D, Savona MR, Fesik SW, Pollyea DA, Jordan CT. PTPN11 Mutations Confer Unique Metabolic Properties and Increase Resistance to Venetoclax and Azacitidine in Acute Myelogenous Leukemia Blood. 132: 909-909. DOI: 10.1182/Blood-2018-99-119806 |
0.382 |
|
| 2018 |
Jones CL, Stevens BM, D'Alessandro A, Culp-Hill R, Reisz J, Ye H, Khan N, Minhajuddin M, DeGregori J, Pollyea DA, Jordan CT. Cysteine and Cystine Depletion Targets Leukemia Stem Cells Blood. 132: 431-431. DOI: 10.1182/Blood-2018-99-113181 |
0.416 |
|
| 2018 |
Walker ZJ, VanWyngarden MJ, Stevens BM, Langouët-Astrie C, Smith C, Palmer BE, Forsberg PA, Mark TM, Jordan CT, Sherbenou DW. A Rapid Functional Screen for Small Molecule and Monoclonal Antibody Drug Sensitivity in Multiple Myeloma Patients Blood. 132: 3203-3203. DOI: 10.1182/Blood-2018-99-111394 |
0.372 |
|
| 2018 |
Jones CL, Stevens BM, Culp-Hill R, Nemkov T, D'Alessandro A, Pei S, Pollyea DA, Jordan CT. Leukemia Stem Cells in Relapsed AML Patients Are Uniquely Dependent on Nicotinamide Metabolism Blood. 132: 429-429. DOI: 10.1182/Blood-2018-99-111366 |
0.387 |
|
| 2018 |
Winters A, Goosman M, Stevens BM, Purev E, Smith C, Pollyea DA, Jordan CT, Gutman JA. Tracking of AML-Associated Mutations Via Droplet Digital PCR Is Predictive of Outcomes Post-Transplant Blood. 132: 2138-2138. DOI: 10.1182/Blood-2018-99-110834 |
0.353 |
|
| 2017 |
Garcia TB, Snedeker JC, Baturin D, Gardner L, Fosmire SP, Zhou C, Jordan CT, Venkataraman S, Vibhakar R, Porter CC. A small molecule inhibitor of WEE1, AZD1775, synergizes with olaparib by impairing homologous recombination and enhancing DNA damage and apoptosis in acute leukemia. Molecular Cancer Therapeutics. PMID 28655785 DOI: 10.1158/1535-7163.Mct-16-0660 |
0.408 |
|
| 2017 |
Janganati V, Ponder J, Thakkar S, Jordan CT, Crooks PA. Succinamide derivatives of melampomagnolide B and their anti-cancer activities. Bioorganic & Medicinal Chemistry. PMID 28545815 DOI: 10.1016/J.Bmc.2017.05.008 |
0.348 |
|
| 2017 |
Bommagani S, Ponder J, Penthala NR, Janganati V, Jordan CT, Borrelli MJ, Crooks PA. Indole carboxylic acid esters of melampomagnolide B are potent anticancer agents against both hematological and solid tumor cells. European Journal of Medicinal Chemistry. 136: 393-405. PMID 28525840 DOI: 10.1016/J.Ejmech.2017.05.031 |
0.356 |
|
| 2017 |
Gasparetto M, Pei S, Minhajuddin M, Khan N, Pollyea DA, Myers JR, Ashton JM, Becker MW, Vasiliou V, Humphries KR, Jordan CT, Smith CA. Targeted therapy for a subset of acute myeloid leukemias that lack expression of aldehyde dehydrogenase 1A1. Haematologica. PMID 28280079 DOI: 10.3324/Haematol.2016.159053 |
0.467 |
|
| 2017 |
Pollyea DA, Jordan CT. Therapeutic targeting of acute myeloid leukemia stem cells. Blood. 129: 1627-1635. PMID 28159738 DOI: 10.1182/Blood-2016-10-696039 |
0.447 |
|
| 2017 |
Zhang W, Stevens BM, Budde EE, Forman SJ, Jordan CT, Purev E. Anti-CD123 CAR T-Cell Therapy for the Treatment of Myelodysplastic Syndrome Blood. 130: 1917-1917. DOI: 10.1182/Blood.V130.Suppl_1.1917.1917 |
0.399 |
|
| 2017 |
Pollyea DA, Stevens BM, Winters A, Minhajuddin M, Gutman JA, Purev E, Smith C, Abbott D, Jordan CT. Venetoclax (Ven) with Azacitidine (Aza) for Untreated Elderly Acute Myeloid Leukemia (AML) Patients (Pts) Unfit for Induction Chemotherapy: Single Center Clinical Experience and Mechanistic Insights from Correlative Studies Blood. 130: 181-181. DOI: 10.1182/Blood.V130.Suppl_1.181.181 |
0.369 |
|
| 2017 |
Stevens BM, Winters A, Gutman JA, Fullerton A, Hemenway G, Miltgen N, Wei Q, Abbasi T, Vali S, Singh NK, Drusbosky LM, Cogle CR, Hammes A, Jordan CT, Pollyea DA. Sequential Azacitidine (Aza) and Lenalidomide (Len) for Patients (Pts) with Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML): Clinical Results and Predictive Modeling Using Computational Analysis and Serial Genomics Blood. 130: 1337-1337. DOI: 10.1182/Blood.V130.Suppl_1.1337.1337 |
0.31 |
|
| 2017 |
Zahreddine H, Kraljacic-Culjkovic B, Cali V, Lauer M, Skrabanek L, Khan N, Midura R, Cerchietti L, Hascall V, Jordan C. Abstract 4898: eIF4E reshapes the surface of migrating AML cells through regulating Hyaluronic Acid synthesis & CD44 expression Cancer Research. 77: 4898-4898. DOI: 10.1158/1538-7445.Am2017-4898 |
0.32 |
|
| 2016 |
Gregory MA, D'Alessandro A, Alvarez-Calderon F, Kim J, Nemkov T, Adane B, Rozhok AI, Kumar A, Kumar V, Pollyea DA, Wempe MF, Jordan CT, Serkova NJ, Tan AC, Hansen KC, et al. ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. 113: E6669-E6678. PMID 27791036 DOI: 10.1073/Pnas.1603876113 |
0.403 |
|
| 2016 |
Li B, Zhao W, Zhang X, Wang J, Luo X, Baker SD, Jordan CT, Dong Y. Design, synthesis and evaluation of anti-CD123 antibody drug conjugates. Bioorganic & Medicinal Chemistry. PMID 27687970 DOI: 10.1016/J.Bmc.2016.09.043 |
0.39 |
|
| 2016 |
Pei S, Minhajuddin M, D'Alessandro A, Nemkov T, Stevens BM, Adane B, Khan N, Hagen FK, Yadav VK, De S, Ashton JM, Hansen KC, Gutman JA, Pollyea DA, Crooks PA, ... ... Jordan CT, et al. Rational Design of a Parthenolide-based Drug Regimen that Selectively Eradicates Acute Myelogenous Leukemia Stem Cells. The Journal of Biological Chemistry. PMID 27573247 DOI: 10.1074/Jbc.M116.750653 |
0.458 |
|
| 2016 |
Ho TC, LaMere M, Stevens BM, Ashton JM, Myers JR, O'Dwyer KM, Liesveld JL, Mendler JH, Guzman M, Morrissette JD, Zhao J, Wang ES, Wetzler M, Jordan CT, Becker MW. Evolution of acute myelogenous leukemia stem cell properties following treatment and progression. Blood. PMID 27421961 DOI: 10.1182/Blood-2016-02-695312 |
0.445 |
|
| 2016 |
Tyagi V, Alwaseem H, O'Dwyer KM, Ponder J, Li QY, Jordan CT, Fasan R. Chemoenzymatic synthesis and antileukemic activity of novel C9- and C14-functionalized parthenolide analogs. Bioorganic & Medicinal Chemistry. PMID 27396927 DOI: 10.1016/J.Bmc.2016.06.028 |
0.325 |
|
| 2016 |
Ye H, Adane B, Khan N, Sullivan T, Minhajuddin M, Gasparetto M, Stevens B, Pei S, Balys M, Ashton JM, Klemm DJ, Woolthuis CM, Stranahan AW, Park CY, Jordan CT. Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche. Cell Stem Cell. PMID 27374788 DOI: 10.1016/J.Stem.2016.06.001 |
0.422 |
|
| 2016 |
Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, Bloomfield CD, Estey E, Burnett A, Cornelissen JJ, Scheinberg DA, Bouscary D, Linch DC. Acute myeloid leukaemia. Nature Reviews. Disease Primers. 2: 16010. PMID 27159408 DOI: 10.1038/nrdp.2016.10 |
0.362 |
|
| 2016 |
Minson KA, Smith CC, DeRyckere D, Libbrecht C, Lee-Sherick AB, Huey MG, Lasater EA, Kirkpatrick GD, Stashko MA, Zhang W, Jordan CT, Kireev D, Wang X, Frye SV, Earp HS, et al. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. Jci Insight. 1: e85630. PMID 27158668 DOI: 10.1172/Jci.Insight.85630 |
0.402 |
|
| 2016 |
Riedel SS, Haladyna JN, Bezzant M, Stevens B, Pollyea DA, Sinha AU, Armstrong SA, Wei Q, Pollock RM, Daigle SR, Jordan CT, Ernst P, Neff T, Bernt KM. MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia. The Journal of Clinical Investigation. PMID 26927674 DOI: 10.1172/Jci80825 |
0.396 |
|
| 2016 |
Stevens BM, Pollyea DA, Khan N, Jordan CT. Distinct Metabolic Properties of MDS Stem Cells Provide Novel Opportunities for Therapeutic Intervention Blood. 128: 4316-4316. DOI: 10.1182/Blood.V128.22.4316.4316 |
0.478 |
|
| 2016 |
Page LS, Wang X, Earp HS, Frye S, Jordan CT, Lee-Sherick AB. MerTK Receptor Tyrosine Kinase Inhibition As a Potential Strategy to Augment Immune-Mediated Clearance of Acute Myeloid Leukemia Blood. 128: 4044-4044. DOI: 10.1182/Blood.V128.22.4044.4044 |
0.383 |
|
| 2016 |
Ye H, Khan N, Minhajuddin M, Adane B, Jordan CT. Adipose Tissue-Derived IGFBP1 Facilitates Progression of Leukemia Blood. 128: 3058-3058. DOI: 10.1182/Blood.V128.22.3058.3058 |
0.335 |
|
| 2016 |
Nooruddin Z, Pan Z, Gross L, David W, Haverkos BM, Pollyea DA, Gutman JA, Robinson W, Smith C, Schowinsky J, Enkhtsetseg P, Sherbenou DW, Rabinovitch R, Ney D, Jordan CT, et al. Post-Transplant Diffuse Large B Cell Lymphoma with Non Germinal Center B-Cell Subtype Frequently Lacks Programmed Cell Death Ligand (PD-L1) Overexpression Which May Influence Overall Outcomes Blood. 128: 3054-3054. DOI: 10.1182/Blood.V128.22.3054.3054 |
0.33 |
|
| 2016 |
Jones CL, Kirkpatrick G, Fleenor C, Seth W, Noetzli LJ, Fosmire S, Baturin D, Liang X, Hernandez G, Pietras EM, Jordan CT, Rowley JW, Di Paola J, Hagman JR, Porter CC. ETV6 Regulates Pax5 Expression in Early B Cell Development Blood. 128: 2655-2655. DOI: 10.1182/Blood.V128.22.2655.2655 |
0.396 |
|
| 2016 |
Pei S, Minhajuddin M, Adane B, Stevens BM, Khan N, D'alessandro A, Nemkov T, Hansen KC, Pollyea DA, Jordan CT. Mitochondrial Fission 1 Regulates GSK3 and AMPK Signaling to Sustain Leukemia Stem Cell Function in Acute Myelogenous Leukemia Blood. 128: 1703-1703. DOI: 10.1182/Blood.V128.22.1703.1703 |
0.391 |
|
| 2016 |
Adane B, Ye H, Pei S, Khan N, Minhajuddin M, Stevens BM, Zaberezhnyy V, Pollyea DA, Jordan CT. The Role of NADPH Oxidase 2 in Normal and Malignant Hematopoiesis Blood. 128: 1079-1079. DOI: 10.1182/Blood.V128.22.1079.1079 |
0.49 |
|
| 2016 |
Riedel S, Haladyna J, Stevens B, Pollyea D, Wei Q, Jordan C, Ernst P, Neff T, Bernt K. Abstract IA11: Meningioma-1 cooperates with MLL and DOT1L to induce leukemia Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-Ia11 |
0.391 |
|
| 2015 |
Baranello MP, Bauer L, Jordan CT, Benoit DSW. Micelle Delivery of Parthenolide to Acute Myeloid Leukemia Cells. Cellular and Molecular Bioengineering. 8: 455-470. PMID 29552235 DOI: 10.1007/S12195-015-0391-X |
0.382 |
|
| 2015 |
Crooks PA, Janganati V, Ponder J, Jordan CT, Borrelli MJ, Penthala NR. Dimers of melampomagnolide B exhibit potent anticancer activity against hematological and solid tumor cells. Journal of Medicinal Chemistry. PMID 26540463 DOI: 10.1021/Acs.Jmedchem.5B01187 |
0.363 |
|
| 2015 |
Stevens B, Maxson J, Tyner J, Smith CA, Gutman JA, Robinson W, Jordan CT, Lee CK, Swisshelm K, Tobin J, Wei Q, Schowinsky J, Rinella S, Lee HG, Pollyea DA. Clonality of Neutrophilia Associated with Plasma Cell Neoplasms: Report of a SETBP1 Mutation and Analysis of a Single Institution Series. Leukemia & Lymphoma. 1-22. PMID 26389776 DOI: 10.3109/10428194.2015.1094697 |
0.347 |
|
| 2015 |
Ammar M, Jordan CT, Cao L, Lim E, Bouchlaka Souissi C, Jrad A, Omrane I, Kouidhi S, Zaraa I, Anbunathan H, Mokni M, Doss N, Guttman-Yassky E, El Gaaied B, Menter A, et al. CARD14 alterations in Tunisian psoriasis patients and further characterization in European cohorts. The British Journal of Dermatology. PMID 26358359 DOI: 10.1111/Bjd.14158 |
0.496 |
|
| 2015 |
Pulvino M, Chen L, Oleksyn D, Li J, Compitello G, Rossi R, Spence S, Balakrishnan V, Jordan C, Poligone B, Casulo C, Burack R, Shapiro JL, Bernstein S, Friedberg JW, et al. Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline. Oncotarget. 6: 14796-813. PMID 26142707 DOI: 10.18632/Oncotarget.4193 |
0.424 |
|
| 2015 |
Koo GB, Morgan MJ, Lee DG, Kim WJ, Yoon JH, Koo JS, Kim SI, Kim SJ, Son MK, Hong SS, Levy JM, Pollyea DA, Jordan CT, Yan P, Frankhouser D, et al. Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Research. 25: 707-25. PMID 25952668 DOI: 10.1038/Cr.2015.56 |
0.345 |
|
| 2015 |
Lee-Sherick AB, Zhang W, Menachof KK, Hill AA, Rinella S, Kirkpatrick G, Page LS, Stashko MA, Jordan CT, Wei Q, Liu J, Zhang D, DeRyckere D, Wang X, Frye S, et al. Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia. Oncotarget. 6: 6722-36. PMID 25762638 DOI: 10.18632/Oncotarget.3156 |
0.344 |
|
| 2015 |
Alvarez-Calderon F, Gregory MA, Pham-Danis C, DeRyckere D, Stevens BM, Zaberezhnyy V, Hill AA, Gemta L, Kumar A, Kumar V, Wempe MF, Pollyea DA, Jordan CT, Serkova NJ, Graham DK, et al. Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1360-72. PMID 25547679 DOI: 10.1158/1078-0432.Ccr-14-2146 |
0.364 |
|
| 2015 |
Smith C, Gasparetto M, Jordan C, Pollyea DA, Vasiliou V. The effects of alcohol and aldehyde dehydrogenases on disorders of hematopoiesis. Advances in Experimental Medicine and Biology. 815: 349-59. PMID 25427917 DOI: 10.1007/978-3-319-09614-8_20 |
0.369 |
|
| 2015 |
Ye H, Adane B, Khan N, Ashton JM, Balys M, Stevens BM, Minhajuddin M, Jordan CT. Adipose Tissue Functions As a Reservoir for Leukemia Stem Cells and Confers Chemo-Resistance Blood. 126: 845-845. DOI: 10.1182/Blood.V126.23.845.845 |
0.373 |
|
| 2015 |
Pei S, Minhajuddin M, Stevens BM, Adane B, Khan N, D'alessandro A, Nemkov T, Hansen KC, Pollyea D, Jordan CT. Regulation of Mitochondrial Morphology Is Important for Leukemia Stem Cell Function Blood. 126: 842-842. DOI: 10.1182/Blood.V126.23.842.842 |
0.379 |
|
| 2015 |
Ho T, Jordan CT, LaMere MW, Ashton JM, O'Dwyer K, Mendler JH, Liesveld JL, Wang ES, Guzman ML, Calvi LM, Becker MW. A Role for IL1RAP in Acute Myelogenous Leukemia Stem Cells Following Treatment and Progression Blood. 126: 4266-4266. DOI: 10.1182/Blood.V126.23.4266.4266 |
0.462 |
|
| 2015 |
Stevens BM, Pollyea D, Khan N, Jordan CT. Characterization and Targeting of Myelodysplastic Syndrome Stem Cells Blood. 126: 4104-4104. DOI: 10.1182/Blood.V126.23.4104.4104 |
0.46 |
|
| 2015 |
Jeyaraju DV, Hurren R, Wang X, MacLean N, Gronda M, Jordan CT, Minden MD, Giaever G, Schimmer AD. A Novel Isoflavone, ME-344, Targets the Cytoskeleton in Acute Myeloid Leukemia Blood. 126: 3682-3682. DOI: 10.1182/Blood.V126.23.3682.3682 |
0.447 |
|
| 2015 |
Ye H, Khan N, Balys M, Ashton JM, Adane B, Jordan CT. Leukemia Cells Resident in Adipose Tissue Display a Pro-Inflammatory Phenotype and Induce Lipolysis and Atrophy of Adipose Tissue Blood. 126: 2765-2765. DOI: 10.1182/Blood.V126.23.2765.2765 |
0.434 |
|
| 2015 |
Riedel S, Haladyna J, Stevens B, Jordan CT, Pollyea D, Armstrong SA, Wei Q, Ernst P, Neff T, Bernt KM. Meningeoma-1 Cooperates with MLL and DOT1L to Induce Leukemia Blood. 126: 2428-2428. DOI: 10.1182/Blood.V126.23.2428.2428 |
0.388 |
|
| 2015 |
Nooruddin Z, Robinson W, Pollyea D, Gutman JA, Smith C, Pan Z, Jordan CT, Rabinovitch R, Schowinsky J, Lu X, Ney D, Kamdar M. IHC Analysis and Prognostic Factors in Post Transplant Lymphoproliferative Disorders after Solid Organ Transplantation: A Single Center Experience Blood. 126: 1443-1443. DOI: 10.1182/Blood.V126.23.1443.1443 |
0.303 |
|
| 2014 |
Kim SW, Schifano M, Oleksyn D, Jordan CT, Ryan D, Insel R, Zhao J, Chen L. Protein kinase C-associated kinase regulates NF-κB activation through inducing IKK activation. International Journal of Oncology. 45: 1707-14. PMID 25096806 DOI: 10.3892/Ijo.2014.2578 |
0.33 |
|
| 2014 |
Pollyea DA, Gutman JA, Gore L, Smith CA, Jordan CT. Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials. Haematologica. 99: 1277-84. PMID 25082785 DOI: 10.3324/Haematol.2013.085209 |
0.438 |
|
| 2014 |
Guzman ML, Yang N, Sharma KK, Balys M, Corbett CA, Jordan CT, Becker MW, Steidl U, Abdel-Wahab O, Levine RL, Marcucci G, Roboz GJ, Hassane DC. Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia. Molecular Cancer Therapeutics. 13: 1979-90. PMID 24934933 DOI: 10.1158/1535-7163.Mct-13-0963 |
0.467 |
|
| 2014 |
Gandhi UH, Kaushal N, Hegde S, Finch ER, Kudva AK, Kennett MJ, Jordan CT, Paulson RF, Prabhu KS. Selenium suppresses leukemia through the action of endogenous eicosanoids. Cancer Research. 74: 3890-901. PMID 24872387 DOI: 10.1158/0008-5472.CAN-13-3694 |
0.332 |
|
| 2014 |
Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, Cormack G, Jaquith JB, Cerchietti L, Cocolakis E, Amri A, Bergeron J, Leber B, Becker MW, Pei S, ... Jordan CT, et al. The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. Nature. 511: 90-3. PMID 24870236 DOI: 10.1038/Nature13283 |
0.331 |
|
| 2014 |
Smith C, Gasparetto M, Humphries K, Pollyea DA, Vasiliou V, Jordan CT. Aldehyde dehydrogenases in acute myeloid leukemia. Annals of the New York Academy of Sciences. 1310: 58-68. PMID 24641679 DOI: 10.1111/Nyas.12414 |
0.456 |
|
| 2014 |
Callahan KP, Minhajuddin M, Corbett C, Lagadinou ED, Rossi RM, Grose V, Balys MM, Pan L, Jacob S, Frontier A, Grever MR, Lucas DM, Kinghorn AD, Liesveld JL, Becker MW, ... Jordan CT, et al. Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity. Leukemia. 28: 1960-8. PMID 24577530 DOI: 10.1038/Leu.2014.93 |
0.502 |
|
| 2014 |
Liu S, Miriyala S, Keaton MA, Jordan CT, Wiedl C, Clair DK, Moscow JA. Metabolic effects of acute thiamine depletion are reversed by rapamycin in breast and leukemia cells. Plos One. 9: e85702. PMID 24454921 DOI: 10.1371/Journal.Pone.0085702 |
0.376 |
|
| 2014 |
Velu CS, Chaubey A, Phelan JD, Horman SR, Wunderlich M, Guzman ML, Jegga AG, Zeleznik-Le NJ, Chen J, Mulloy JC, Cancelas JA, Jordan CT, Aronow BJ, Marcucci G, Bhat B, et al. Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. The Journal of Clinical Investigation. 124: 222-36. PMID 24334453 DOI: 10.1172/Jci66005 |
0.398 |
|
| 2014 |
Kolev JN, O'Dwyer KM, Jordan CT, Fasan R. Discovery of potent parthenolide-based antileukemic agents enabled by late-stage P450-mediated C-H functionalization. Acs Chemical Biology. 9: 164-73. PMID 24206617 DOI: 10.1021/Cb400626W |
0.347 |
|
| 2014 |
Riedel S, Bernt KM, Haladyna J, Bezzant M, Stevens B, Pollyea DA, Sinha AU, Armstrong SA, Wei Q, Jordan CT, Neff T. Targeting Meningeoma-1 Driven AML through Epigenetic Modulation of the Cell of Origin Blood. 124: 838-838. DOI: 10.1182/Blood.V124.21.838.838 |
0.437 |
|
| 2014 |
Gasparetto M, Pei S, Minhajuddin M, Pollyea DA, Vasiliou V, Humphries RK, Jordan CT, Smith CA. Aldehyde Dehydrogenases Play a Role in Acute Myeloid Leukemia and Have Prognostic and Therapeutic Significance Blood. 124: 2238-2238. DOI: 10.1182/Blood.V124.21.2238.2238 |
0.461 |
|
| 2014 |
Velu CS, Chaubey A, Phelan JD, Meyer S, Horman SR, Wunderlich M, Guzman ML, Jegga AG, Zeleznik-Le NJ, Chen J, Mulloy JC, Cancelas JA, Jordan CT, Aronow BJ, Marcucci G, et al. Abstract 979: microRNA-mediated leukemia-initiating cell activity Cancer Research. 74: 979-979. DOI: 10.1158/1538-7445.Am2014-979 |
0.393 |
|
| 2013 |
Pei S, Minhajuddin M, Callahan KP, Balys M, Ashton JM, Neering SJ, Lagadinou ED, Corbett C, Ye H, Liesveld JL, O'Dwyer KM, Li Z, Shi L, Greninger P, Settleman J, ... ... Jordan CT, et al. Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells. The Journal of Biological Chemistry. 288: 33542-58. PMID 24089526 DOI: 10.1074/Jbc.M113.511170 |
0.464 |
|
| 2013 |
Miller PG, Al-Shahrour F, Hartwell KA, Chu LP, Järås M, Puram RV, Puissant A, Callahan KP, Ashton J, McConkey ME, Poveromo LP, Cowley GS, Kharas MG, Labelle M, Shterental S, ... ... Jordan CT, et al. In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell. 24: 45-58. PMID 23770013 DOI: 10.1016/J.Ccr.2013.05.004 |
0.447 |
|
| 2013 |
Sen S, Hassane DC, Corbett C, Becker MW, Jordan CT, Guzman ML. Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity. Experimental Hematology. 41: 799-807.e4. PMID 23660068 DOI: 10.1016/J.Exphem.2013.04.012 |
0.344 |
|
| 2013 |
Nielsen TH, Johnson N, Garnier N, Kwan S, Yao L, Cocolakis E, Hébert J, Morgan RA, Paquet E, Callahan KP, Jordan CT, Assouline S, Miller WH, Mann KK. Monitoring Response and Resistance to the Novel Arsenical Darinaparsin in an AML Patient. Frontiers in Pharmacology. 4: 9. PMID 23408639 DOI: 10.3389/Fphar.2013.00009 |
0.374 |
|
| 2013 |
Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, Ashton JM, Pei S, Grose V, O'Dwyer KM, Liesveld JL, Brookes PS, Becker MW, Jordan CT. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 12: 329-41. PMID 23333149 DOI: 10.1016/J.Stem.2012.12.013 |
0.373 |
|
| 2013 |
Ammar M, Bouchlaka-Souissi C, Helms CA, Zaraa I, Jordan CT, Anbunathan H, Bouhaha R, Kouidhi S, Doss N, Dhaoui R, Ben Osman A, Ben Ammar El Gaied A, Marrakchi R, Mokni M, Bowcock AM. Genome-wide linkage scan for psoriasis susceptibility loci in multiplex Tunisian families. The British Journal of Dermatology. 168: 583-7. PMID 23013406 DOI: 10.1111/Bjd.12050 |
0.485 |
|
| 2013 |
Sampson ER, McMurray HR, Hassane DC, Newman L, Salzman P, Jordan CT, Land H. Gene signature critical to cancer phenotype as a paradigm for anticancer drug discovery. Oncogene. 32: 3809-18. PMID 22964631 DOI: 10.1038/Onc.2012.389 |
0.338 |
|
| 2013 |
Gasparetto M, Jordan CT, Minhajuddin M, Pollyea DA, Vasilou V, Reigan P, Humphries RK, Smith CA. ALDH Genes and Reactive Aldehydes Play Important Roles in HSCs and Leukemia and May Be Exploited to Treat AML Blood. 122: 2893-2893. DOI: 10.1182/Blood.V122.21.2893.2893 |
0.403 |
|
| 2012 |
Pei S, Jordan CT. How close are we to targeting the leukemia stem cell? Best Practice & Research. Clinical Haematology. 25: 415-8. PMID 23200537 DOI: 10.1016/J.Beha.2012.10.003 |
0.463 |
|
| 2012 |
Ashton JM, Balys M, Neering SJ, Hassane DC, Cowley G, Root DE, Miller PG, Ebert BL, McMurray HR, Land H, Jordan CT. Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells. Cell Stem Cell. 11: 359-72. PMID 22863534 DOI: 10.1016/J.Stem.2012.05.024 |
0.45 |
|
| 2012 |
Jordan CT, Cao L, Roberson ED, Duan S, Helms CA, Nair RP, Duffin KC, Stuart PE, Goldgar D, Hayashi G, Olfson EH, Feng BJ, Pullinger CR, Kane JP, Wise CA, et al. Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. American Journal of Human Genetics. 90: 796-808. PMID 22521419 DOI: 10.1016/J.Ajhg.2012.03.013 |
0.509 |
|
| 2012 |
Jordan CT, Cao L, Roberson ED, Pierson KC, Yang CF, Joyce CE, Ryan C, Duan S, Helms CA, Liu Y, Chen Y, McBride AA, Hwu WL, Wu JY, Chen YT, et al. PSORS2 is due to mutations in CARD14. American Journal of Human Genetics. 90: 784-95. PMID 22521418 DOI: 10.1016/J.Ajhg.2012.03.012 |
0.736 |
|
| 2012 |
Zhao C, Xiu Y, Ashton J, Xing L, Morita Y, Jordan CT, Boyce BF. Noncanonical NF-κB signaling regulates hematopoietic stem cell self-renewal and microenvironment interactions. Stem Cells (Dayton, Ohio). 30: 709-18. PMID 22290873 DOI: 10.1182/Blood.V118.21.859.859 |
0.405 |
|
| 2012 |
Frisch BJ, Ashton JM, Xing L, Becker MW, Jordan CT, Calvi LM. Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia. Blood. 119: 540-50. PMID 21957195 DOI: 10.1182/Blood-2011-04-348151 |
0.425 |
|
| 2012 |
Liesveld JL, O'Dwyer K, Becker MW, Mulford D, Walker A, Chen R, Bechelli J, Rosell K, Jordan CT, Minhajuddin M, Phillips GL. Phase I Study of Decitabine and Rapamycin in Relapsed/Refractory Acute Myelogenous Leukemia Blood. 120: 3549-3549. DOI: 10.1182/Blood.V120.21.3549.3549 |
0.372 |
|
| 2012 |
Lagadinou ED, Sach A, Callahan KP, Rossi RM, Neering S, Pei S, O'Dwyer K, Liesveld JL, Brookes PS, Becker MW, Jordan CT. Bcl-2 Inhibitor ABT-263 Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells Blood. 120: 206-206. DOI: 10.1182/Blood.V120.21.206.206 |
0.461 |
|
| 2012 |
Callahan KP, Corbett C, Jacob S, Minhajuddin M, Lagadinou ED, Rossi RM, Gross V, Balys M, Hagen F, Frontier AJ, Jordan CT. Rocaglamide Selectively Eradicates Human Leukemia Stem Cells and Synergizes with Multiple Agents to Target AML Cells Blood. 120: 1338-1338. DOI: 10.1182/Blood.V120.21.1338.1338 |
0.504 |
|
| 2011 |
Becker MW, Jordan CT. Leukemia stemness signatures step toward the clinic. Cell Stem Cell. 9: 185-6. PMID 21885015 DOI: 10.1016/J.Stem.2011.08.006 |
0.405 |
|
| 2011 |
Benito J, Shi Y, Szymanska B, Carol H, Boehm I, Lu H, Konoplev S, Fang W, Zweidler-McKay PA, Campana D, Borthakur G, Bueso-Ramos C, Shpall E, Thomas DA, Jordan CT, et al. Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. Plos One. 6: e23108. PMID 21853076 DOI: 10.1371/Journal.Pone.0023108 |
0.461 |
|
| 2011 |
Nasim S, Guzman ML, Jordan CT, Crooks PA. Discovery of 1,2,4-thiadiazolidine-3,5-dione analogs that exhibit unusual and selective rapid cell death kinetics against acute myelogenous leukemia cells in culture. Bioorganic & Medicinal Chemistry Letters. 21: 4879-83. PMID 21757349 DOI: 10.1016/J.Bmcl.2011.06.027 |
0.416 |
|
| 2011 |
Liesveld JL, Rosell KE, Bechelli J, Lu C, Messina P, Mulford D, Ifthikharuddin JJ, Jordan CT, Phillips Ii GL. Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines. Cancer Investigation. 29: 439-50. PMID 21740082 DOI: 10.3109/07357907.2011.590567 |
0.42 |
|
| 2011 |
Nasim S, Pei S, Hagen FK, Jordan CT, Crooks PA. Melampomagnolide B: a new antileukemic sesquiterpene. Bioorganic & Medicinal Chemistry. 19: 1515-9. PMID 21273084 DOI: 10.1016/J.Bmc.2010.12.045 |
0.336 |
|
| 2011 |
Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 591-9. PMID 21220598 DOI: 10.1200/Jco.2010.31.0904 |
0.437 |
|
| 2011 |
Becker MW, Jordan CT. Leukemia stem cells in 2010: current understanding and future directions. Blood Reviews. 25: 75-81. PMID 21216511 DOI: 10.1016/J.Blre.2010.11.001 |
0.458 |
|
| 2011 |
Brigham PMGS, Miller W, Al-Shahrour F, Hartwell KA, Chu LP, Marcus J, Puram RV, Puissant A, Callahan K, Ashton JM, McConkey ME, Poveromo L, Cowley G, Kharas MG, Labelle M, ... ... Jordan CT, et al. In Vivo RNA Interference Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling Blood. 118: 758-758. DOI: 10.1182/Blood.V118.21.758.758 |
0.368 |
|
| 2011 |
Lagadinou E, Callahan K, Neering SJ, Pei S, Minhajuddin M, Rossi RM, Grose V, Corbett C, Balys M, Brookes P, Jordan CT. Reactive Oxygen Species (ROS) Levels Define Functional Heterogeneity in Human Leukemia Stem Cells and Represent a Critical Parameter for Therapeutic Targeting Blood. 118: 639-639. DOI: 10.1182/Blood.V118.21.639.639 |
0.483 |
|
| 2011 |
Ashton JM, Balys M, Neering S, Cowley G, Root DE, Miller PG, Ebert B, McMurray H, Hassane DC, Land H, Jordan CT. Oncogene Cooperativity Analysis Reveals a Novel Set of Genes That Regulate the In Vivo Growth and Survival of Leukemia Stem Cells Blood. 118: 553-553. DOI: 10.1182/Blood.V118.21.553.553 |
0.46 |
|
| 2011 |
Pei S, Callahan K, Minhajuddin M, Balys M, Neering S, Corbett C, Becker MW, Liesveld JL, Hagen F, Friedman AE, Crooks P, Jordan CT. Targeting Redox Homeostasis As a Means to Selectively Eradicate Primary Human Leukemia Cells, Blood. 118: 3506-3506. DOI: 10.1182/Blood.V118.21.3506.3506 |
0.488 |
|
| 2011 |
Minhajuddin M, Pei S, Ashton JM, Callahan K, Lagadinou E, Balys M, Corbett C, Neering S, Rossi RM, Jordan CT. Molecular Mechanisms of Parthenolide-Mediated Pro-Apoptotic Activity in Acute Myeloid Leukemia Cells Blood. 118: 2463-2463. DOI: 10.1182/Blood.V118.21.2463.2463 |
0.447 |
|
| 2011 |
Hassane DC, Leon JPD, Corbett C, Rossi RM, Xie W, Jordan CT, Guzman ML. Troglitazone and Prochloroperazine Repositioned As An Anti-Leukemia Stem Cell Drug Combination Using Chemical Genomics-Based Prediction Blood. 118: 1885-1885. DOI: 10.1182/Blood.V118.21.1885.1885 |
0.368 |
|
| 2011 |
Xie W, Hassane DC, Jordan CT, Roboz GJ, Guzman ML. High Throughput Screening Reveals Unique Sensitivity of CD34+CD38- AML Cells to Isotretinoin and Tretinoin Blood. 118: 1430-1430. DOI: 10.1182/Blood.V118.21.1430.1430 |
0.386 |
|
| 2011 |
Yang N, Hassane DC, Balys M, Corbett CA, Jordan CT, Guzman ML. Abstract 2145: AR-42, a novel histone deacetylase inhibitor with selectivity against leukemia stem cell via apoptosis induction, inhibition of chaperone function of heat shock protein 90 in acute myeloid leukemia Cancer Research. 71: 2145-2145. DOI: 10.1158/1538-7445.Am2011-2145 |
0.455 |
|
| 2010 |
Hassane DC, Sen S, Minhajuddin M, Rossi RM, Corbett CA, Balys M, Wei L, Crooks PA, Guzman ML, Jordan CT. Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood. 116: 5983-90. PMID 20889920 DOI: 10.1182/Blood-2010-04-278044 |
0.403 |
|
| 2010 |
Dai Y, Guzman ML, Chen S, Wang L, Yeung SK, Pei XY, Dent P, Jordan CT, Grant S. The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. British Journal of Haematology. 151: 70-83. PMID 20701602 DOI: 10.1111/J.1365-2141.2010.08319.X |
0.433 |
|
| 2010 |
Silvers CR, Williams K, Salamone L, Huang J, Jordan CT, Zhou H, Palapattu GS. A novel in vitro assay of tumor-initiating cells in xenograft prostate tumors. The Prostate. 70: 1379-87. PMID 20687210 DOI: 10.1002/Pros.21171 |
0.316 |
|
| 2010 |
Ito T, Kwon HY, Zimdahl B, Congdon KL, Blum J, Lento WE, Zhao C, Lagoo A, Gerrard G, Foroni L, Goldman J, Goh H, Kim SH, Kim DW, Chuah C, ... ... Jordan CT, et al. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature. 466: 765-8. PMID 20639863 DOI: 10.1038/Nature09171 |
0.352 |
|
| 2010 |
Jordan CT. Targeting myeloid leukemia stem cells. Science Translational Medicine. 2: 31ps21. PMID 20463365 DOI: 10.1126/Scitranslmed.3000914 |
0.424 |
|
| 2010 |
Cairo MS, Jordan CT, Maley CC, Chao C, Melnick A, Armstrong SA, Shlomchik W, Molldrem J, Ferrone S, Mackall C, Zitvogel L, Bishop MR, Giralt SA, June CH. NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 16: 709-28. PMID 20227509 DOI: 10.1016/J.Bbmt.2010.03.002 |
0.406 |
|
| 2010 |
Benito J, Shi Y, Szymanska B, Carol H, Bohem I, Lu H, Konoplev S, Fang W, Kornblau SM, Zweidler-McKay P, Wilson W, Campana D, Borthakur G, Bueso-Ramos CE, Kantarjian HM, ... ... Jordan CT, et al. Targeting the Leukemia-Associated Hypoxic Microenvironment with Hypoxia-Activated Prodrug PR-104 Blood. 116: 868-868. DOI: 10.1182/Blood.V116.21.868.868 |
0.45 |
|
| 2010 |
Chaubey A, Velu CS, Horman S, Jegga A, Guzman ML, Zeleznik-Le N, Jordan CT, Carroll M, Gebelein B, Grimes HL. Intrinsic Requirement of MicroRNA In Hox-Based Leukemia Initiating Cell Maintenance Blood. 116: 4192-4192. DOI: 10.1182/Blood.V116.21.4192.4192 |
0.382 |
|
| 2010 |
Lagadinou ED, Kokkinou D, Siapati E, Vassilopoulos G, Jordan CT, Spyridonidis A. Isolation and Functional Characterization of a Novel “Oxidative State – low” Leukemic Population with Stem Cell Properties and Potential Resistance to Chemotherapy In Acute Myeloid Leukemia. Blood. 116: 1580-1580. DOI: 10.1182/Blood.V116.21.1580.1580 |
0.481 |
|
| 2010 |
Frisch BJ, Ashton JM, Jordan CT, Calvi LM. Microenvironmental Changes In An In Vivo Model of Myeloid Leukemia Negatively Regulate Osteoblastic Cells. Blood. 116: 1219-1219. DOI: 10.1182/Blood.V116.21.1219.1219 |
0.358 |
|
| 2010 |
Ito T, Kwon HY, Zimdahl B, Congdon KL, Blum J, Lento WE, Zhao C, Lagoo A, Gerrard G, Foroni L, Goldman J, Goh H, Kim S, Kim D, Chuah C, ... ... Jordan CT, et al. P73. Regulation of myeloid leukemia by the cell fate determinant Musashi Differentiation. 80: S41. DOI: 10.1016/J.Diff.2010.09.079 |
0.364 |
|
| 2009 |
Skalska J, Brookes PS, Nadtochiy SM, Hilchey SP, Jordan CT, Guzman ML, Maggirwar SB, Briehl MM, Bernstein SH. Modulation of cell surface protein free thiols: a potential novel mechanism of action of the sesquiterpene lactone parthenolide. Plos One. 4: e8115. PMID 19956548 DOI: 10.1371/Journal.Pone.0008115 |
0.396 |
|
| 2009 |
Frisch BJ, Porter RL, Gigliotti BJ, Olm-Shipman AJ, Weber JM, O'Keefe RJ, Jordan CT, Calvi LM. In vivo prostaglandin E2 treatment alters the bone marrow microenvironment and preferentially expands short-term hematopoietic stem cells. Blood. 114: 4054-63. PMID 19726721 DOI: 10.1182/Blood-2009-03-205823 |
0.403 |
|
| 2009 |
Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. Science (New York, N.Y.). 324: 1670-3. PMID 19556499 DOI: 10.1126/Science.1171837 |
0.383 |
|
| 2009 |
Woodward WA, Bristow RG, Clarke MF, Coppes RP, Cristofanilli M, Duda DG, Fike JR, Hambardzumyan D, Hill RP, Jordan CT, Milas L, Pajonk F, Curran WJ, Dicker AP, Chen Y. Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trials. International Journal of Radiation Oncology, Biology, Physics. 74: 1580-91. PMID 19540073 DOI: 10.1016/J.Ijrobp.2009.03.047 |
0.358 |
|
| 2009 |
Neelakantan S, Nasim S, Guzman ML, Jordan CT, Crooks PA. Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1). Bioorganic & Medicinal Chemistry Letters. 19: 4346-9. PMID 19505822 DOI: 10.1016/J.Bmcl.2009.05.092 |
0.317 |
|
| 2009 |
Korver W, Zhao X, Singh S, Pardoux C, Zhao J, Guzman ML, Sen S, Yonkovich S, Liu S, Zhan X, Tomasevic N, Zhou C, Gros D, Jordan CT, Gotlib J, et al. Monoclonal antibodies against IREM-1: potential for targeted therapy of AML. Leukemia. 23: 1587-97. PMID 19440216 DOI: 10.1038/Leu.2009.99 |
0.453 |
|
| 2009 |
Guzman ML, Jordan CT. Lessons learned from the study of JunB: new insights for normal and leukemia stem cell biology. Cancer Cell. 15: 252-4. PMID 19345324 DOI: 10.1016/J.Ccr.2009.03.008 |
0.406 |
|
| 2009 |
Jordan CT. Cancer stem cells: controversial or just misunderstood? Cell Stem Cell. 4: 203-5. PMID 19265659 DOI: 10.1016/J.Stem.2009.02.003 |
0.38 |
|
| 2009 |
Jordan CT. Making Sense of Leukemia Stem Cells: Our Current Understanding and Future Directions. Blood. 114. DOI: 10.1182/Blood.V114.22.Sci-36.Sci-36 |
0.417 |
|
| 2009 |
Chaubey A, Velu CS, Horman S, Jegga A, Guzman ML, Risner L, Zeleznik-Le NJ, Jordan CT, Carroll M, Gebelein B, Grimes HL. Epigenetic Signaling Is Required for HoxA9-Based Leukemic Transformation. Blood. 114: 3966-3966. DOI: 10.1182/Blood.V114.22.3966.3966 |
0.37 |
|
| 2009 |
Hassane D, Sen S, Corbett CA, Balys M, Rossi RM, Crooks PA, Guzman ML, Jordan CT. Chemical Genomic Screening Reveals That PI3K/mTOR Inhibition Enhances Activity of the Anti-Leukemia Stem Cell Compound Parthenolide. Blood. 114: 388-388. DOI: 10.1182/Blood.V114.22.388.388 |
0.474 |
|
| 2009 |
Skalska J, Brookes PS, Nadtochy SM, Hilchey S, Jordan CT, Guzman ML, Maggirwar S, Briehl MM, Bernstein SH. Modulation of Cell Surface Protein Free Thiols; A Potential Novel Mechanism of Action of the Sesquiterpene Lactone Parthenolide in Non-Hodgkin's Lymphoma. Blood. 114: 3774-3774. DOI: 10.1182/Blood.V114.22.3774.3774 |
0.414 |
|
| 2009 |
Guzman ML, Nasim S, Balys M, Corbett CA, Crooks PA, Jordan CT. Chemical Derivatives of the Anti-Leukemia Stem Cell Compound 4-Benzyl-2-Methyl-1,2,4-Thiadiazolidine-3,5-Dione (TDZD-8) with Improved Activity. Blood. 114: 3764-3764. DOI: 10.1182/Blood.V114.22.3764.3764 |
0.437 |
|
| 2009 |
Ashton JM, Hassane D, Neering S, Bushnell TP, Jordan CT. Synergistically Regulated Genes and Pathways in Leukemias Induced by Co-Expression of BCR-ABL and Nup98-HoxA9. Blood. 114: 3473-3473. DOI: 10.1182/Blood.V114.22.3473.3473 |
0.484 |
|
| 2009 |
Rossi RM, Grose V, Pine P, Fisher RI, Jordan CT, Friedberg JW. Rational Combinations Including a Novel Syk Inhibitor, Fostamatinib Disodium (FosD) in Diffuse Large B Cell Lymphoma. Blood. 114: 283-283. DOI: 10.1182/Blood.V114.22.283.283 |
0.414 |
|
| 2009 |
Pei S, Guzman ML, Nasim S, Shi L, Crooks PA, Jordan CT. Analysis of the Anti-Leukemia Mechanism of Parthenolide. Blood. 114: 2734-2734. DOI: 10.1182/Blood.V114.22.2734.2734 |
0.434 |
|
| 2009 |
Wiedl CM, Horton TM, Rossi RM, Neering SJ, Grose V, Jordan CT. Heterogeneity in Phenotype, Functional Capacity, and Drug Sensitivity for Pediatric Acute Leukemia. Blood. 114: 2654-2654. DOI: 10.1182/Blood.V114.22.2654.2654 |
0.426 |
|
| 2009 |
Hassane D, Balys M, Marcucci G, Byrd JC, Jordan CT, Guzman ML. Identification of the Histone Deacetylase Inhibitor (HDACi), AR-42, as a Novel Anti-Leukemia Stem Cell Agent in Acute Myeloid Leukemia (AML). Blood. 114: 2070-2070. DOI: 10.1182/Blood.V114.22.2070.2070 |
0.456 |
|
| 2009 |
Wuensch SA, Rossi RM, Burack R, Rothberg PG, Jordan CT, Young FM. Clonally Related B-NHL Populations and Cell Lines Harbor Subsets with Significant Phenotypic and Functional Heterogeneity. Blood. 114: 1699-1699. DOI: 10.1182/Blood.V114.22.1699.1699 |
0.391 |
|
| 2009 |
Guzman ML, Schuurhuis GJ, Jordan CT. Targeting acute myelogenous leukemia stem cells Cancer Stem Cells. 93-108. DOI: 10.1017/CBO9780511605536.007 |
0.317 |
|
| 2008 |
Hewamana S, Lin TT, Jenkins C, Burnett AK, Jordan CT, Fegan C, Brennan P, Rowntree C, Pepper C. The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 8102-11. PMID 19088025 DOI: 10.1158/1078-0432.Ccr-08-1673 |
0.376 |
|
| 2008 |
Jordan CT. Can we finally target the leukemic stem cells? Best Practice & Research. Clinical Haematology. 21: 615-20. PMID 19041600 DOI: 10.1016/J.Beha.2008.07.006 |
0.427 |
|
| 2008 |
Wang PY, Young F, Chen CY, Stevens BM, Neering SJ, Rossi RM, Bushnell T, Kuzin I, Heinrich D, Bottaro A, Jordan CT. The biologic properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF gene. Blood. 112: 4184-92. PMID 18755985 DOI: 10.1182/Blood-2008-02-142190 |
0.476 |
|
| 2008 |
Mendler JH, Kelly J, Voci S, Marquis D, Rich L, Rossi RM, Bernstein SH, Jordan CT, Liesveld J, Fisher RI, Friedberg JW. Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 19: 1759-64. PMID 18504251 DOI: 10.1093/Annonc/Mdn365 |
0.32 |
|
| 2008 |
Young FM, Campbell A, Emo KL, Jansson J, Wang PY, Jordan CT, Mullen CA. High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 14: 622-30. PMID 18489987 DOI: 10.1016/J.Bbmt.2008.02.015 |
0.412 |
|
| 2008 |
Hassane DC, Guzman ML, Corbett C, Li X, Abboud R, Young F, Liesveld JL, Carroll M, Jordan CT. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood. 111: 5654-62. PMID 18305216 DOI: 10.1182/Blood-2007-11-126003 |
0.458 |
|
| 2008 |
Mao G, Yuan F, Absher K, Jennings CD, Howard DS, Jordan CT, Gu L. Preferential loss of mismatch repair function in refractory and relapsed acute myeloid leukemia: potential contribution to AML progression. Cell Research. 18: 281-9. PMID 18227862 DOI: 10.1038/Cr.2008.14 |
0.322 |
|
| 2008 |
Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, Guzman ML, Jordan CT, Neelakantan S, Crooks PA, Burnett AK, Pratt G, Fegan C, Rowntree C, Brennan P, Pepper C. The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood. 111: 4681-9. PMID 18227347 DOI: 10.1182/Blood-2007-11-125278 |
0.337 |
|
| 2008 |
Kim SW, Oleksyn DW, Rossi RM, Jordan CT, Sanz I, Chen L, Zhao J. Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells. Blood. 111: 1644-53. PMID 18025152 DOI: 10.1182/Blood-2007-05-088591 |
0.433 |
|
| 2008 |
Korver W, Zhao X, Singh S, Pardoux C, Zhao J, Sen S, Guzman ML, Jordan CT, Hsi ED, Abo A. CLL-1, a Receptor Expressed on Myeloid Leukemic Stem Cells, Is a Potential Target for Immunotherapy of AML Blood. 112: 4003-4003. DOI: 10.1182/Blood.V112.11.4003.4003 |
0.484 |
|
| 2008 |
Hassane DC, Ashton JM, Guzman ML, Jordan CT. Genes Dysregulated in a Murine Model of Leukemogenesis Comprise a Signature for Identification of Therapeutics in Humans. Blood. 112: 3349-3349. DOI: 10.1182/Blood.V112.11.3349.3349 |
0.46 |
|
| 2008 |
Frisch B, Ashton JM, Olm-shipman A, Xing L, Jordan CT, Calvi L. Reciprocal Synergistic Interactions of Leukemic Cells with Osteoclast Progenitors in the Bone Microenvironment Blood. 112: 322-322. DOI: 10.1182/Blood.V112.11.322.322 |
0.405 |
|
| 2008 |
Howard D, Liesveld J, Phillips GL, Guzman ML, Jordan CT. A Phase I study using Bortezomib with Weekly Idarubicin for the Treatment of Elderly (>60 YEARS) and Relapsed Patients with Acute Myeloid Leukemia (AML) Blood. 112: 2953-2953. DOI: 10.1182/Blood.V112.11.2953.2953 |
0.338 |
|
| 2008 |
Rossi RM, Balys M, Franklin D, Grose V, Fisher RI, Jordan C. Inhibition of Human Lymphoma Cell Growth by the PKC-Beta Selective Inhibitor Enzastaurin (LY317615) in Combination with Multiple Therapeutic Agents. Blood. 112: 1595-1595. DOI: 10.1182/Blood.V112.11.1595.1595 |
0.401 |
|
| 2007 |
Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, Becker MW, Bennett JM, Sullivan E, Lachowicz JL, Vaughan A, Sweeney CJ, Matthews W, Carroll M, Liesveld JL, ... ... Jordan CT, et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood. 110: 4427-35. PMID 17804695 DOI: 10.1182/Blood-2007-05-090621 |
0.473 |
|
| 2007 |
Guzman ML, Li X, Corbett CA, Rossi RM, Bushnell T, Liesveld JL, Hébert J, Young F, Jordan CT. Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood. 110: 4436-44. PMID 17785584 DOI: 10.1182/Blood-2007-05-088815 |
0.498 |
|
| 2007 |
Neering SJ, Bushnell T, Sozer S, Ashton J, Rossi RM, Wang PY, Bell DR, Heinrich D, Bottaro A, Jordan CT. Leukemia stem cells in a genetically defined murine model of blast-crisis CML. Blood. 110: 2578-85. PMID 17601986 DOI: 10.1182/Blood-2007-02-073031 |
0.498 |
|
| 2007 |
Jordan CT. The leukemic stem cell. Best Practice & Research. Clinical Haematology. 20: 13-8. PMID 17336250 DOI: 10.1016/J.Beha.2006.10.005 |
0.466 |
|
| 2007 |
Hassane DC, Guzman ML, Corbett C, Li X, Liesveld JL, Young F, Carroll M, Jordan CT. A Search of Public Gene Expression Microarray Data Identifies Novel Agents That Selectively Eradicate AML Stem Cells. Blood. 110: 776-776. DOI: 10.1182/Blood.V110.11.776.776 |
0.457 |
|
| 2007 |
Murakami M, Xia J, Jordan CT, Boxer LA, Dale D, Bolyard AA, Dinauer MC, Link DC. Granulocytic Precursors from Patients with ELA2-Mutant Severe Congenital Neutropenia Display a Transcriptional Profile Consistent with Activation of the Unfolded Protein Response. Blood. 110: 662-662. DOI: 10.1182/Blood.V110.11.662.662 |
0.383 |
|
| 2007 |
Friedberg JW, Kelly J, Voci S, Marquis D, Rich L, Rossi R, Bernstein S, Jordan C, Liesveld J, Fisher RI. Bortezomib and Gemcitabine in Relapsed Hodgkin Lymphoma (HL). Blood. 110: 2325-2325. DOI: 10.1182/Blood.V110.11.2325.2325 |
0.346 |
|
| 2007 |
Frisch BJ, Weber JM, Porter RL, Gigliotti BJ, Smith JN, Olm-Shipman AJ, O’Keefe RJ, Jordan CT, Calvi LM. In Vivo Treatment with Prostaglandin E2 (PGE2) Selectively Expands Short-Term Hematopoietic Stem Cells. Blood. 110: 1254-1254. DOI: 10.1182/Blood.V110.11.1254.1254 |
0.403 |
|
| 2006 |
Jordan CT. Searching for leukemia stem cells--not yet the end of the road? Cancer Cell. 10: 253-4. PMID 17045202 DOI: 10.1016/J.Ccr.2006.09.010 |
0.463 |
|
| 2006 |
Jordan CT, Guzman ML, Noble M. Cancer stem cells. The New England Journal of Medicine. 355: 1253-61. PMID 16990388 DOI: 10.1056/Nejmra061808 |
0.375 |
|
| 2006 |
Weber JM, Forsythe SR, Christianson CA, Frisch BJ, Gigliotti BJ, Jordan CT, Milner LA, Guzman ML, Calvi LM. Parathyroid hormone stimulates expression of the Notch ligand Jagged1 in osteoblastic cells. Bone. 39: 485-93. PMID 16647886 DOI: 10.1016/J.Bone.2006.03.002 |
0.377 |
|
| 2006 |
Calvi LM, Frisch BJ, Gigliotti BJ, Christianson CA, Weber JM, Jordan CT, O’Keefe RJ. Prostaglandin E2 (PGE2) Regulates Osteoblastic Jagged1 and Expands Primitive Hematopoietic Cells In Vivo. Blood. 108: 89-89. DOI: 10.1182/Blood.V108.11.89.89 |
0.375 |
|
| 2006 |
Mullen CA, Campbell A, Young F, Jordan CT. Pre-B Cell Acute Lymphoblastic Leukemia Cells Carrying a Bcr/Abl Translocation Retain Sensitivity to Minor Histocompatibility Antigen Specific T Cells but Are Resistant to Natural Killer Cells: Implications for Manipulation of Graft Versus Leukemia Effects. Blood. 108: 3247-3247. DOI: 10.1182/Blood.V108.11.3247.3247 |
0.457 |
|
| 2006 |
Hassane DC, Guzman ML, Li X, Corbett C, Jordan CT. Molecular Signature for Parthenolide-Induced Apoptosis in AML CD34+ Cells Reveals Targets for Improving Induction of Leukemia-Specific Cell Death. Blood. 108: 2592-2592. DOI: 10.1182/Blood.V108.11.2592.2592 |
0.459 |
|
| 2006 |
Guzman ML, Li X, Corbett C, Rossi RM, Bushnell T, Jordan CT. Rapid Loss of Membrane Integrity and Irreversible Commitment to Cell Death of Primary AML Stem Cells: A Novel Activity for 4-benzyl, 2-methyl,1,2,4-Thiadiazolidine,3,5 Dione (TDZD-8). Blood. 108: 2535-2535. DOI: 10.1182/Blood.V108.11.2535.2535 |
0.483 |
|
| 2006 |
Guzman ML, Rossi RM, Li X, Corbett C, Hassane DC, Bushnell T, Carroll M, Sullivan E, Neelakantan S, Crooks PA, Jordan CT. A Novel Orally Available Parthenolide Analog Selectively Eradicates AML Stem and Progenitor Cells. Blood. 108: 237-237. DOI: 10.1182/Blood.V108.11.237.237 |
0.488 |
|
| 2006 |
Jordan CT, Neering SJ, Wang P, Rossi RM, Bushnell T. In Vivo Analyses of Leukemia Stem Cells in Genetically Defined Murine Models of Chronic and Blast Crisis CML. Blood. 108: 236-236. DOI: 10.1182/Blood.V108.11.236.236 |
0.499 |
|
| 2005 |
Jordan CT. The potential of targeting malignant stem cells as a treatment for leukemia. Future Oncology (London, England). 1: 205-7. PMID 16555992 DOI: 10.1517/14796694.1.2.205 |
0.458 |
|
| 2005 |
Jordan CT. Targeting the most critical cells: approaching leukemia therapy as a problem in stem cell biology. Nature Clinical Practice. Oncology. 2: 224-5. PMID 16264940 DOI: 10.1038/Ncponc0164 |
0.467 |
|
| 2005 |
Guzman ML, Jordan CT. Feverfew: weeding out the root of leukaemia. Expert Opinion On Biological Therapy. 5: 1147-52. PMID 16120045 DOI: 10.1517/14712598.5.9.1147 |
0.469 |
|
| 2005 |
Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS, Jordan CT. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood. 105: 4163-9. PMID 15687234 DOI: 10.1182/Blood-2004-10-4135 |
0.507 |
|
| 2005 |
Guzman ML, Li X, Corbett C, Hassane DC, Jordan CT. Mechanisms Controlling Selective Death of Leukemia Stem Cells in Response to Parthenolide. Blood. 106: 467-467. DOI: 10.1182/Blood.V106.11.467.467 |
0.469 |
|
| 2005 |
Wang P, Young F, Rossi RM, Bushnell T, Jordan CT. Modeling the Origins of Lymphoid Blast Crisis Via Expression of BCR/ABL in Hematopoietic Cells Mutated at the INK4a/ARF Locus. Blood. 106: 464-464. DOI: 10.1182/Blood.V106.11.464.464 |
0.455 |
|
| 2005 |
Rossi RM, Henn AD, Conkling R, Guzman ML, Bushnell T, Harvey J, Fisher RI, Jordan CT. The PKCβ Selective Inhibitor, Enzastaurin (LY317615), Inhibits Growth of Human Lymphoma Cells. Blood. 106: 1483-1483. DOI: 10.1182/Blood.V106.11.1483.1483 |
0.395 |
|
| 2005 |
Nolta JA, Jordan CT. The gold standard improves: A better assay for HSCs Blood. 106: 1141-1142. DOI: 10.1182/Blood-2005-05-2064 |
0.404 |
|
| 2004 |
Gilliland DG, Jordan CT, Felix CA. The molecular basis of leukemia. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 80-97. PMID 15561678 DOI: 10.1182/Asheducation-2004.1.80 |
0.465 |
|
| 2004 |
Jordan CT. Cancer stem cell biology: from leukemia to solid tumors. Current Opinion in Cell Biology. 16: 708-12. PMID 15530785 DOI: 10.1016/J.Ceb.2004.09.002 |
0.377 |
|
| 2004 |
Jordan CT. A new approach to treatment of acute myelogenous leukemia using targeted therapy in combination with standard chemotherapy. Leukemia Research. 28: 1121-2. PMID 15380333 DOI: 10.1016/J.Leukres.2004.05.019 |
0.31 |
|
| 2004 |
Jordan CT, Guzman ML. Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene. 23: 7178-87. PMID 15378078 DOI: 10.1038/Sj.Onc.1207935 |
0.455 |
|
| 2004 |
Liesveld JL, Jordan CT, Phillips GL. The hematopoietic stem cell in myelodysplasia. Stem Cells (Dayton, Ohio). 22: 590-9. PMID 15277704 DOI: 10.1634/Stemcells.22-4-590 |
0.45 |
|
| 2004 |
Jordan CT, Roback JD. Separating antiviral and GVHD activities of donor T cells prior to bone marrow transplantation. Immunologic Research. 29: 209-18. PMID 15181283 DOI: 10.1385/Ir:29:1-3:209 |
0.343 |
|
| 2004 |
Goodrum F, Jordan CT, Terhune SS, High K, Shenk T. Differential outcomes of human cytomegalovirus infection in primitive hematopoietic cell subpopulations. Blood. 104: 687-95. PMID 15090458 DOI: 10.1182/Blood-2003-12-4344 |
0.335 |
|
| 2004 |
Guzman ML, Jordan CT. Considerations for targeting malignant stem cells in leukemia. Cancer Control : Journal of the Moffitt Cancer Center. 11: 97-104. PMID 15024346 DOI: 10.1177/107327480401100216 |
0.474 |
|
| 2004 |
Jordan CT, Zimring JC, Roback JD. Effects of Amotosalen Hydrochloride and Ultraviolet a Light on CD4 and CD8 Cells. Blood. 104: 4981-4981. DOI: 10.1182/Blood.V104.11.4981.4981 |
0.375 |
|
| 2004 |
Sozer S, Echlin DR, Rossi RM, Grimes BA, Jordan CT. Characterization and Functional Analysis of a Murine Model for Chronic Myeloid Leukemia Stem Cells. Blood. 104: 4476-4476. DOI: 10.1182/Blood.V104.11.4476.4476 |
0.469 |
|
| 2004 |
Guzman ML, Karnischky L, Li X, Neering SJ, Rossi RM, Jordan CT. Selective Induction of Apoptosis in Acute Myelogenous Leukemia Stem Cells by the Novel Agent Parthenolide. Blood. 104: 2542-2542. DOI: 10.1182/Blood.V104.11.2542.2542 |
0.508 |
|
| 2004 |
Goodrum FD, Jordan CT, Terhune SS, High KP, Shenk T. Human Cytomegalovirus Infection of Primitive Hematopoietic Progenitor Cells: A Model for Latency. Blood. 104: 1703-1703. DOI: 10.1182/Blood.V104.11.1703.1703 |
0.331 |
|
| 2004 |
Calvi LM, Weber JM, Guzman ML, Christianson CA, Milner LM, Jordan CT. Osteoblastic Cells and the Hematopoietic Microenvironment: The Notch ligand Jagged1 Is Increased in Osteoblastic Stromal Cells by Parathyroid Hormone (PTH)Treatment. Blood. 104: 1284-1284. DOI: 10.1182/Blood.V104.11.1284.1284 |
0.46 |
|
| 2002 |
Srour EF, Jordan CT. Isolation and characterization of primitive hematopoietic cells based on their position in the cell cycle. Methods in Molecular Medicine. 63: 93-111. PMID 21437802 DOI: 10.1385/1-59259-140-X:093 |
0.454 |
|
| 2002 |
Goodrum FD, Jordan CT, High K, Shenk T. Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells: a model for latency. Proceedings of the National Academy of Sciences of the United States of America. 99: 16255-60. PMID 12456880 DOI: 10.1073/Pnas.252630899 |
0.353 |
|
| 2002 |
Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RM, Szilvassy SJ, Jordan CT. Preferential induction of apoptosis for primary human leukemic stem cells. Proceedings of the National Academy of Sciences of the United States of America. 99: 16220-5. PMID 12451177 DOI: 10.1073/Pnas.252462599 |
0.498 |
|
| 2002 |
Gong S, Lu X, Xu Y, Swiderski CF, Jordan CT, Moscow JA. Identification of OCT6 as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemias. Experimental Hematology. 30: 1162-9. PMID 12384147 DOI: 10.1016/S0301-472X(02)00901-3 |
0.405 |
|
| 2002 |
Jordan CT. Unique molecular and cellular features of acute myelogenous leukemia stem cells. Leukemia. 16: 559-62. PMID 11960332 DOI: 10.1038/sj.leu.2402446 |
0.343 |
|
| 2001 |
Jordan CT, Vanin EF, Marini FC. The use of adenoviral vectors for genetic manipulation and analysis of primitive hematopoietic cells. Current Gene Therapy. 1: 257-65. PMID 12109141 DOI: 10.2174/1566523013348535 |
0.421 |
|
| 2001 |
Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, Luger SM, Jordan CT. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 98: 2301-7. PMID 11588023 DOI: 10.1182/Blood.V98.8.2301 |
0.461 |
|
| 2001 |
Guzman ML, Upchurch D, Grimes B, Howard DS, Rizzieri DA, Luger SM, Phillips GL, Jordan CT. Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells. Blood. 97: 2177-9. PMID 11264190 DOI: 10.1182/Blood.V97.7.2177 |
0.448 |
|
| 2001 |
Lemischka IR, Jordan CT. The return of clonal marking sheds new light on human hematopoietic stem cells. Nature Immunology. 2: 11-2. PMID 11135569 DOI: 10.1038/83115 |
0.394 |
|
| 2000 |
Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, Meyerrose T, Rossi R, Grimes B, Rizzieri DA, Luger SM, Phillips GL. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 14: 1777-84. PMID 11021753 DOI: 10.1038/Sj.Leu.2401903 |
0.391 |
|
| 1999 |
Howard DS, Rizzierri DA, Grimes B, Upchurch D, Phillips GL, Stewart AK, Yannelli JR, Jordan CT. Genetic manipulation of primitive leukemic and normal hematopoietic cells using a novel method of adenovirus-mediated gene transfer. Leukemia. 13: 1608-16. PMID 10516763 DOI: 10.1038/Sj.Leu.2401541 |
0.341 |
|
| 1999 |
Rosenzweig M, MacVittie TJ, Harper D, Hempel D, Glickman RL, Johnson RP, Farese AM, Whiting-Theobald N, Linton GF, Yamasaki G, Jordan CT, Malech HL. Efficient and durable gene marking of hematopoietic progenitor cells in nonhuman primates after nonablative conditioning. Blood. 94: 2271-86. PMID 10498599 DOI: 10.1182/Blood.V94.7.2271.419K41_2271_2286 |
0.452 |
|
| 1999 |
Nicola MD, Milanesi M, Magni M, Bregni M, Carlo-Stella C, Longoni P, Tomanin R, Ravagnani F, Scarpa M, Jordan C, Gianni AM. Recombinant adenoviral vector-lipofectAMINE complex for gene transduction into human T lymphocytes. Human Gene Therapy. 10: 1875-1884. PMID 10446927 DOI: 10.1089/10430349950017554 |
0.363 |
|
| 1999 |
Case SS, Price MA, Jordan CT, Yu XJ, Wang L, Bauer G, Haas DL, Xu D, Stripecke R, Naldini L, Kohn DB, Crooks GM. Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. Proceedings of the National Academy of Sciences of the United States of America. 96: 2988-93. PMID 10077624 DOI: 10.1073/Pnas.96.6.2988 |
0.342 |
|
| 1998 |
Jordan CT, Van Zant G. Recent progress in identifying genes regulating hematopoietic stem cell function and fate. Current Opinion in Cell Biology. 10: 716-20. PMID 9914177 DOI: 10.1016/S0955-0674(98)80112-9 |
0.422 |
|
| 1998 |
Bregni M, Shammah S, Malaffo F, Di Nicola M, Milanesi M, Magni M, Matteucci P, Ravagnani F, Jordan CT, Siena S, Gianni AM. Adenovirus vectors for gene transduction into mobilized blood CD34+ cells. Gene Therapy. 5: 465-72. PMID 9614570 DOI: 10.1038/Sj.Gt.3300620 |
0.373 |
|
| 1997 |
Orlic D, Girard LJ, Anderson SM, Do BK, Seidel NE, Jordan CT, Bodine DM. Transduction efficiency of cell lines and hematopoietic stem cells correlates with retrovirus receptor mRNA levels. Stem Cells (Dayton, Ohio). 15: 23-8; discussion 28-. PMID 9368321 DOI: 10.1002/Stem.5530150805 |
0.353 |
|
| 1996 |
Orlic D, Girard LJ, Jordan CT, Anderson SM, Cline AP, Bodine DM. The level of mRNA encoding the amphotropic retrovirus receptor in mouse and human hematopoietic stem cells is low and correlates with the efficiency of retrovirus transduction. Proceedings of the National Academy of Sciences of the United States of America. 93: 11097-102. PMID 8855315 DOI: 10.1073/Pnas.93.20.11097 |
0.354 |
|
| 1996 |
Neering SJ, Hardy SF, Minamoto D, Jordan CT. Transduction of primitive human hematopoietic cells with recombinant adenovirus vectors Experimental Hematology. 24: 1057. DOI: 10.1182/Blood.V88.4.1147.Bloodjournal8841147 |
0.409 |
|
| 1994 |
Zeigler FC, Bennett BD, Jordan CT, Spencer SD, Baumhueter S, Carroll KJ, Hooley J, Bauer K, Matthews W. Cellular and molecular characterization of the role of the flk-2/flt-3 receptor tyrosine kinase in hematopoietic stem cells. Blood. 84: 2422-30. PMID 7919361 DOI: 10.1182/Blood.V84.8.2422.Bloodjournal8482422 |
0.406 |
|
| 1991 |
Matthews W, Jordan CT, Gavin M, Jenkins NA, Copeland NG, Lemischka IR. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proceedings of the National Academy of Sciences of the United States of America. 88: 9026-30. PMID 1717995 DOI: 10.1073/Pnas.88.20.9026 |
0.364 |
|
| 1991 |
Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell. 65: 1143-52. PMID 1648448 DOI: 10.1016/0092-8674(91)90010-V |
0.426 |
|
| 1990 |
Jordan CT, McKearn JP, Lemischka IR. Cellular and developmental properties of fetal hematopoietic stem cells. Cell. 61: 953-63. PMID 1972037 DOI: 10.1016/0092-8674(90)90061-I |
0.431 |
|
| 1990 |
Jordan CT, Lemischka IR. Clonal and systemic analysis of long-term hematopoiesis in the mouse. Genes & Development. 4: 220-32. PMID 1970972 DOI: 10.1101/Gad.4.2.220 |
0.414 |
|
| Show low-probability matches. |